CD8A and neoplasm: CD8 + T cells and dendritic cells are subsequently accelerated to be recruited and activated to induce anti-tumor immune effects in the tumor site.6 Immune checkpoint inhibitors (ICIs) not only activate CD8 + T cells but also normalizes the tumor vasculature system to reduce the tumor hypoxia state and increase tumor radiosensitivity.7 However, the efficacy of this combination is influenced by multiple factors, including the therapeutic sequence and the use of combination drugs.